Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Yizhen Liu, Lingyu Liu, Chuanxu Liu, Wenhao Zhang, Shiyu Jiang, Qunling Zhang, Fangfang Lyu, Xiaojian Liu, Junning Cao, Xuejun Ma, Rong Tao

Blood (2024) 144 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2024-202237

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Efficacy and Safety of Telpegfilgrastim in the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Lymphoma: A Retrospective Study

Yanbin Zheng, Siping Zou, Jianyang Lin, Jiesong Wang, Chang Wang, Guangliang Chen, Junning Cao, Hongming He

Blood (2024) 144 (Supplement 1): 6523.

https://doi.org/10.1182/blood-2024-206847

Published: 2024

Journal Articles

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Guang-Liang Chen, Jia Jin, Hui Sun, Yizhen Liu, Qunling Zhang, Zuguang Xia, Junning Cao, Xiaonan Hong, Fangfang Lv

Blood (2024) 144 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2024-194111

Published: 2024

Journal Articles

Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study

Jia Jin, Yalan Wang, Xi Wang, Yonghong Tang, Shan Zeng, Juan Du, Junning Cao

Blood (2024) 144 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2024-200585

Published: 2024

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study

Jia Jin, Yalan Wang, Xi Wang, Yonghong Tang, Shan Zeng, Juan Du, Junning Cao

Blood (2023) 142 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2023-181529

Published: 2023

Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood (2023) 142 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2023-178710

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Guangliang Chen, Kai Xue, Qunling Zhang, Jia Jin, Yizhen Liu, Zuguang Xia, Fangfang Lyu, Xiaonan Hong, Xiaoqiu LI, Junning Cao

Blood (2023) 142 (Supplement 1): 5805.

https://doi.org/10.1182/blood-2023-174307

Published: 2023

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2023-180373

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Guang-Liang Chen, Pin Guo, Shiyu Jiang, Juan J. Gu, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Rong TAO, Fangfang Lv

Blood (2022) 140 (Supplement 1): 3790–3791.

https://doi.org/10.1182/blood-2022-156877

Published: 2022

Journal Articles

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Yuqin Song, Won-Seog Kim, Dok-Hyun Yoon, Haiyan Yang, Junning Cao, Dongmei Ji, Youngil Koh, Hongmei Jing, Hyeon-Seok Eom, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Jie Jin, Mei Wang, Jingrun Li, Jun Zhu

Blood (2022) 140 (Supplement 1): 6545–6546.

https://doi.org/10.1182/blood-2022-162947

Published: 2022

Journal Articles

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Yizhen Liu, Qunling Zhang, Fangfang Lv, Xiaojian Liu, Dongmei Ji, Zuguang Xia, Jia Jin, Rong TAO, Wenhao Zhang, Xiaoqiu Li, Shengjian Zhang, Jiachen Wang, Xiaonan Hong, Junning Cao

Blood (2022) 140 (Supplement 1): 6627–6628.

https://doi.org/10.1182/blood-2022-158657

Published: 2022

Journal Articles

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang, Keshu Zhou, Ying Cheng, Liling Zhang, Haiyan Yang, Liqun Zou, Junning Cao, Huiqiang Huang, Ye Guo, Zhao Wang, Sha Huang, Zhiyu Liang, Hui Yao, Haiyi Guo, Yiqian Fang, Hongjie Zhu

Blood (2022) 140 (Supplement 1): 3750–3752.

https://doi.org/10.1182/blood-2022-155979

Published: 2022

Journal Articles

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Juan J Gu, Paola Ghione, Shiyu Jiang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Dongmei Ji, Junning Cao, Xiaonan Hong, Xuejun Ma, Qunling Zhang

Blood (2021) 138 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2021-149229

Published: 2021

NARROW

Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Efficacy and Safety of Telpegfilgrastim in the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Lymphoma: A Retrospective Study

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only